Transitioning to a new era in cervical cancer screening

Gynecologic Oncology

Volumn 136, Issue 2, 2015, Pages 175-177

  Schiffman, Mark ^a   Wentzensen, Nicolas ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; COLPOSCOPY; CYTOLOGY; EDITORIAL; EMERGENCY HEALTH SERVICE; FEMALE; GENOTYPE; HIGH RISK POPULATION; HISTORY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOCHEMISTRY; PAPANICOLAOU TEST; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAFETY; TREATMENT PLANNING; UTERINE CERVIX CANCER; WART VIRUS; ISOLATION AND PURIFICATION; MASS SCREENING; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIROLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84923016766     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.01.538     Document Type: Editorial

References (23)

1. T.C. Wright, M.H. Stoler, C.M. Behrens, A. Sharma, G. Zhang, and T.L. Wright Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test Gynecol. Oncol. 2015
2. R.S. Hoda, K. Loukeris, and F.W. Abdul-Karim Gynecologic cytology on conventional and liquid-based preparations: a comprehensive review of similarities and differences Diagn. Cytopathol. 41 2013 257 278
3. A.G. Siebers, P.J. Klinkhamer, J.M. Grefte, L.F. Massuger, J.E. Vedder, A. Beijers-Broos, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial JAMA 302 2009 1757 1764
4. M.H. Einstein, M.G. Martens, F.A. Garcia, D.G. Ferris, A.L. Mitchell, S.P. Day, et al. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology Gynecol. Oncol. 118 2010 116 122
5. M. Schiffman, A. Hildesheim, R. Herrero, and C. Bratti Human papillomavirus testing as a screening tool for cervical cancer JAMA 283 2000 2525 2526
6. J.T. Cox, P.E. Castle, C.M. Behrens, A. Sharma, T.C. Wright Jr., and J. Cuzick Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study Am. J. Obstet. Gynecol. 208 184 2013 e1 e11
7. P.E. Castle, M. Schiffman, C.M. Wheeler, and D. Solomon Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2 Obstet. Gynecol. 113 2009 18 25
8. M. Schiffman, P.E. Castle, J. Jeronimo, A.C. Rodriguez, and S. Wacholder Human papillomavirus and cervical cancer Lancet 370 2007 890 907
9. H.A. Katki, W.K. Kinney, B. Fetterman, T. Lorey, N.E. Poitras, L. Cheung, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice Lancet Oncol. 12 2011 663 672
10. W.K. Huh, K.A. Ault, D. Chelmow, D.D. Davey, R.A. Goulart, F.A. Garcia, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance Obstet. Gynecol. 2015
11. N. Wentzensen, L. Schwartz, R.E. Zuna, K. Smith, C. Mathews, M.A. Gold, et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population Clin. Cancer Res. 18 2012 4154 4162
12. K.U. Petry, D. Schmidt, S. Scherbring, A. Luyten, A. Reinecke-Luthge, C. Bergeron, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 dual-stained cytology Gynecol. Oncol. 121 2011 505 509
13. C. Bergeron, G. Ronco, M. Reuschenbach, N. Wentzensen, M. Arbyn, M. Stoler, et al. The clinical impact of using p16 immunochemistry in cervical histopathology and cytology: an update of recent developments Int. J. Cancer 2014
14. M.A. Clarke, N. Wentzensen, L. Mirabello, A. Ghosh, S. Wacholder, A. Harari, et al. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer Cancer Epidemiol. Biomarkers Prev. 2012
15. K. Louvanto, E.L. Franco, A.V. Ramanakumar, N. Vasiljevic, D. Scibior-Bentkowska, A. Koushik, et al. Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16 Int. J. Cancer 136 2015 E638 E645
16. D. Saslow, D. Solomon, H.W. Lawson, M. Killackey, S.L. Kulasingam, J. Cain, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer CA Cancer J. Clin. 2012
17. M.A. Vink, J.A. Bogaards, C.J. Meijer, and J. Berkhof Primary human papillomavirus DNA screening for cervical cancer prevention: can the screening interval be safely extended? Int. J. Cancer 2014
18. J.C. Gage, M. Schiffman, H.A. Katki, P.E. Castle, B. Fetterman, N. Wentzensen, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test J. Natl. Cancer Inst. 106 2014
19. W. Kinney, T.C. Wright, H.E. Dinkelspiel, M. DeFrancesco, J.T. Cox, and W. Huh Increased cervical cancer risk associated with screening at longer intervals Obstet. Gynecol. 2015
20. N. Wentzensen, J.L. Walker, M.A. Gold, K.M. Smith, R.E. Zuna, C. Mathews, et al. Multiple biopsies and detection of cervical cancer precursors at colposcopy J. Clin. Oncol. 33 2015 83 89
21. T.M. Darragh, T.J. Colgan, J.T. Cox, D.S. Heller, M.R. Henry, R.D. Luff, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology Arch. Pathol. Lab. Med. 136 2012 1266 1297
22. H.A. Katki, M. Schiffman, P.E. Castle, B. Fetterman, N.E. Poitras, T. Lorey, et al. Benchmarking CIN 3 + risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines J. Low. Genit. Tract Dis. 17 2013 S28 S35
23. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J. Clin. 61 2011 69 90